ZA200107521B - Protease inhibitors that overcome drug resistance. - Google Patents

Protease inhibitors that overcome drug resistance.

Info

Publication number
ZA200107521B
ZA200107521B ZA200107521A ZA200107521A ZA200107521B ZA 200107521 B ZA200107521 B ZA 200107521B ZA 200107521 A ZA200107521 A ZA 200107521A ZA 200107521 A ZA200107521 A ZA 200107521A ZA 200107521 B ZA200107521 B ZA 200107521B
Authority
ZA
South Africa
Prior art keywords
drug resistance
protease inhibitors
overcome drug
overcome
protease
Prior art date
Application number
ZA200107521A
Inventor
Jordan J N Tang
Arun K Ghosh
Original Assignee
Oklahoma Med Res Found
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found, Univ Illinois filed Critical Oklahoma Med Res Found
Publication of ZA200107521B publication Critical patent/ZA200107521B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200107521A 1999-02-19 2001-09-12 Protease inhibitors that overcome drug resistance. ZA200107521B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12083599P 1999-02-19 1999-02-19

Publications (1)

Publication Number Publication Date
ZA200107521B true ZA200107521B (en) 2003-06-25

Family

ID=22392823

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200107521A ZA200107521B (en) 1999-02-19 2001-09-12 Protease inhibitors that overcome drug resistance.

Country Status (4)

Country Link
EP (1) EP1155009A2 (en)
AU (1) AU3369200A (en)
WO (1) WO2000048466A2 (en)
ZA (1) ZA200107521B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336134B1 (en) 1998-06-23 2016-08-31 The United States of America, represented by the Secretary, Department of Health and Human Services Fitness assay and methods for reducing resistance of HIV to therapy
HN2002000136A (en) 2001-06-11 2003-07-31 Basf Ag INHIBITORS OF THE PROTEASE OF HIV VIRUS, COMPOUNDS CONTAINING THEMSELVES, THEIR PHARMACEUTICAL USES AND THE MATERIALS FOR SYNTHESIS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874745A (en) * 1987-10-01 1989-10-17 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
DE3841732A1 (en) * 1988-12-10 1990-06-13 Hoechst Ag DIPEPTIDE DERIVATIVES WITH ENZYME-INHIBITOR EFFECT
WO1992003472A1 (en) * 1990-08-24 1992-03-05 The Upjohn Company Peptides containing amino-polyols as transition-state mimics
ES2112880T3 (en) * 1991-11-08 1998-04-16 Merck & Co Inc HIV PROTEASE INHIBITORS USEFUL FOR AIDS TREATMENT.

Also Published As

Publication number Publication date
EP1155009A2 (en) 2001-11-21
WO2000048466A2 (en) 2000-08-24
AU3369200A (en) 2000-09-04
WO2000048466A3 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
ZA200109890B (en) Metalloprotease inhibitors.
HK1045650A1 (en) Pharmaceutical composition.
MXPA03000771A (en) New pharmaceutical composition.
MXPA01013362A (en) ANTI-alphav.
HK1049438A1 (en) Sub-tenon drug delivery.
HK1041885A1 (en) Amide derivatives.
ZA200410015B (en) Pharmaceutical salts.
ZA200101012B (en) Pharmaceutical combinations.
ZA200200477B (en) 2-pyrazolin-5-ones.
HK1054384A1 (en) 4-Pyrimidinyl-n-acyl-l-phenylalanines.
ZA200202537B (en) Pour-on-formulations.
MXPA03004885A (en) Connection base.
HK1051199A1 (en) New phenylpiperazines.
HK1053470A1 (en) 4-Pyridinyln-acyl-l-phenylalanines.
ZA200203707B (en) Pharmaceutical combinations.
ZA200000857B (en) Pharmaceutical composition.
ZA200108646B (en) Electrodes.
ZA200110053B (en) Factor via inhibitors.
ZA200205482B (en) Aminosulfonylbiphenyl derivatives.
ZA200206150B (en) Aminomethyl-phenyl-cyclohexanone derivatives.
ZA200110454B (en) Pharmaceutical complex.
ZA200408787B (en) Pharmaceutical combination.
ZA200107521B (en) Protease inhibitors that overcome drug resistance.
MXPA03004542A (en) Protease inhibitors.
HK1046133A1 (en) Pharmaceutical compounds.